Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Soleno Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Soleno Therapeutics Inc (SLNO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 3,958,294 | $331,625,871 | -12% | 33.94% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 3,575,964 | $299,594,264 | -19% | 0.5% |
| 3. | VenBio Select Advisor Kurt Von Emster | 2,050,000 | $171,749,000 | -19% | 3.01% |
| 4. | Citadel Investment Group Ken Griffin | 1,505,161 | $126,102,388 | -5% | 0.02% |
| 5. | Holocene Advisors Brandon Haley | 1,153,048 | $96,602,361 | -4% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 250,000 | $5,000,000.00 | 3,074,542 | 2023-09-28 | Filing | |
| $21.00 | 36,939 | $775,719.00 | 2,824,542 | 2023-09-26 | Filing | |
| $20.03 | 117,996 | $2,363,459.88 | 2,787,603 | 2023-09-26 | Filing | |
| $19.11 | 88,685 | $1,694,770.35 | 2,669,607 | 2023-09-26 | Filing | |
| $18.24 | 52,691 | $961,083.84 | 2,580,922 | 2023-09-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.76 | 3,830 | $316,970.80 | 13,206 | 2025-07-01 | Filing | |
| $84.25 | 266 | $22,410.50 | 17,036 | 2025-06-24 | Filing | |
| $70.11 | 3,782 | $265,156.02 | 27,036 | 2025-04-01 | Filing | |
| $71.55 | 5,937 | $424,797.10 | 6,500 | 2025-03-28 | Filing | |
| $66.95 | 23,475 | $1,571,716.98 | 28,143 | 2025-03-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,308,009 | $444,593,980 | 0.22% | |
| 2. | 3,337,858 | $279,645,737 | 0.02% | |
| 3. | 2,844,747 | $238,332,903 | 0% | |
| 4. | 2,487,832 | $208,430,565 | 0% | |
| 5. | 1,429,756 | $119,784,958 | 0.5% |
News See All
Soleno Therapeutics' Vykat XR Exceeds Sales Expectations
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025.
11 Best Performing Mid Cap Stocks So Far In 2025
On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds.
10 Unstoppable Stocks to Buy According to Hedge Funds
As per Morgan Stanley, investors can see gains in equities and high-quality fixed income for 2025, despite a slowdown in global economic growth. In the Midyear Investment Outlook, Morgan Stanley Research...
FDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter.
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an ‘Overweight’ rating on the stock with a $145 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Soleno Therapeutics, Inc.
11 Best Performing Healthcare Stocks to Buy Now
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector.